CYTOGENETIC STUDY IN MULTIPLE-MYELOMA AT DIAGNOSIS - COMPARISON OF 2 TECHNIQUES

被引:45
作者
SMADJA, NV
LOUVET, C
ISNARD, F
DUTEL, JL
GRANGE, M
VARETTE, C
KRULIK, M
机构
[1] HOP COMPIEGNE,UNITE HEMATOL ONCOL,PARIS,FRANCE
[2] HOP BICHAT,F-75877 PARIS,FRANCE
关键词
MULTIPLE MYELOMA; CYTOGENETIC STUDIES;
D O I
10.1111/j.1365-2141.1995.tb05593.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytogenetic studies in multiple myeloma (MM) have been disappointing due to the low mitotic index of plasma cells. Recently the detection of clonal chromosomal abnormalities at diagnosis seemed to be improved by addition of cytokines (IL-6 and GM-CSF) in the culture medium. We performed two parallel total bone marrow cells culture types in 33 stage I, II and III multiple myeloma patients at diagnosis: 3 d without any cytokine, and 4-7 days stimulated with IL-6 and GM-CSF, No clonal chromosomal abnormality was detected in the 12 stage I and II patients either in 3 d or in 4-7 d culture. In stage III patients, abnormalities were observed in 18/21 (85.7%) and in 8/18 (44.4%) in the 3 d culture and the 4-7 d stimulated cultures respectively, Our results suggest that in stage III multiple myeloma at diagnosis, 3 d culture without cytokine may be the better technique to detect clonal chromosomal abnormalities, and, before using cytokines as a reference condition, this 3 d unstimulated culture should be considered.
引用
收藏
页码:619 / 624
页数:6
相关论文
共 18 条
[1]  
Bataille R., Jourdan M., Zhang X.G., Klein B., Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias, Journal of Clinical Investigation, 84, pp. 2008-2011, (1989)
[2]  
Chiesa J.J., (1991)
[3]  
Dewald G.W., Kyle R.A., Hicks G.A., Greipp P.R., The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis, Blood, 66, pp. 380-390, (1985)
[4]  
Durie B.G.M., Salmon S.E., A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival, Cancer, 36, pp. 842-854, (1975)
[5]  
Facon T., Lai J.L., Nataf E., Preudhomme C, Zandecki M., Hammad M., Wattel E., Jouet J.P., Bauters F., Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients, British Journal of Haematology, 84, pp. 743-745, (1993)
[6]  
Facon T., Lai J.L., Trillot N., Flactif M., Zandecki M., Bauters F., Cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in patients with multiple myeloma: a report on 100 patients. (Abstract), Blood, 82, (1993)
[7]  
Gould J., Alexanian R., Goodacre A., Pathak S., Hecht B., Barlogie B., Plasma cell karyotype in multiple myeloma, Blood, 71, pp. 453-456, (1988)
[8]  
Guidelines for Cancer Cytogenetics. Supplement to: An International System for Human Cytogenetic Nomenclature, (1991)
[9]  
Klein B., Zhang X.G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R., Paracrine rather than autocrine regulation of myeloma‐cell growth and differentiation by interleukin‐6, Blood, 73, pp. 517-526, (1989)
[10]  
Liang W., Hopper J.E., Rowley J.D., Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemic disorders, Cancer, 44, pp. 630-644, (1979)